ES8600938A1 - Un procedimiento para preparar el antigeno de superficie de la hepatitis b - Google Patents

Un procedimiento para preparar el antigeno de superficie de la hepatitis b

Info

Publication number
ES8600938A1
ES8600938A1 ES532730A ES532730A ES8600938A1 ES 8600938 A1 ES8600938 A1 ES 8600938A1 ES 532730 A ES532730 A ES 532730A ES 532730 A ES532730 A ES 532730A ES 8600938 A1 ES8600938 A1 ES 8600938A1
Authority
ES
Spain
Prior art keywords
virus
hepatitis
yeast
sequence
surface antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES532730A
Other languages
English (en)
Other versions
ES532730A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline RIT
Original Assignee
SmithKline RIT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline RIT filed Critical SmithKline RIT
Publication of ES8600938A1 publication Critical patent/ES8600938A1/es
Publication of ES532730A0 publication Critical patent/ES532730A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

METODO DE PREPARACION DEL ANTIGENO DE SUPERFICIE DE LA HEPATITIS B. CONSISTE EN LA INSERCION DE CELULAS DE LEVADURA CORRESPONDIENTE A CEPAS DE S. CERAVISIAE DE UNA MOLECULA DE ADN RECOMBINANTE QUE COMPRENDE UNA SECUENCIA DE NUCLEOTIDOS QUE PUEDE CODIFICAR EL VIRUS DE LA HEPATITIS B Y UNA REGION REGULADORA DERIVADA DEL GEN ARG 3 DE LEVADURA EL CUAL PUEDE EFECTUAR LA TRANSCRIPCION DE LA SECUENCIA DEL CITADO VIRUS EN LEVADURA; CULTIVO DE LA LEVADURA Y RECOGIDA DEL VIRUS DE LA HEPATITIS B QUE SE PRODUCE. LA SECUENCIA DEL VIRUS ESTA SUSTITUIDA RESPECTO A LA REGION REGULADORA DE MODO QUE EL VIRUS SINTETIZADO POR LA EXPRESION ESTA SUSTANCIALMENTE EXENTO DE RESIDUOS DE AMINOACIDOS EXTRAÑOS. ESTE VIRUS TIENE APLICACION PARA LA PREPARACION DE VACUNAS DEL VIRUS DE LA HEPATITIS B.
ES532730A 1982-09-08 1984-05-23 Un procedimiento para preparar el antigeno de superficie de la hepatitis b Granted ES532730A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41578982A 1982-09-08 1982-09-08

Publications (2)

Publication Number Publication Date
ES8600938A1 true ES8600938A1 (es) 1985-10-16
ES532730A0 ES532730A0 (es) 1985-10-16

Family

ID=23647197

Family Applications (4)

Application Number Title Priority Date Filing Date
ES525439A Expired ES8506350A1 (es) 1982-09-08 1983-09-07 Un procedimiento para preparar una molecula de dna recombinante
ES532730A Granted ES532730A0 (es) 1982-09-08 1984-05-23 Un procedimiento para preparar el antigeno de superficie de la hepatitis b
ES532732A Expired ES8600939A1 (es) 1982-09-08 1984-05-23 Un procedimiento para preparar una vacuna para el virus de la hepatitis b
ES532731A Granted ES532731A0 (es) 1982-09-08 1984-05-23 Un procedimiento para preparar un vector que comprende la region reguladora arg3 de levadura y un sitio de restriccion proximo a ella

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES525439A Expired ES8506350A1 (es) 1982-09-08 1983-09-07 Un procedimiento para preparar una molecula de dna recombinante

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES532732A Expired ES8600939A1 (es) 1982-09-08 1984-05-23 Un procedimiento para preparar una vacuna para el virus de la hepatitis b
ES532731A Granted ES532731A0 (es) 1982-09-08 1984-05-23 Un procedimiento para preparar un vector que comprende la region reguladora arg3 de levadura y un sitio de restriccion proximo a ella

Country Status (22)

Country Link
EP (1) EP0106828B1 (es)
JP (5) JPS5971694A (es)
KR (1) KR840006014A (es)
AT (1) ATE91718T1 (es)
AU (4) AU584580B2 (es)
CA (1) CA1222707A (es)
CY (1) CY1932A (es)
DE (1) DE3382704T2 (es)
DK (1) DK406483A (es)
ES (4) ES8506350A1 (es)
FI (1) FI833205A7 (es)
GR (1) GR78982B (es)
HK (1) HK1004570A1 (es)
HU (1) HU196625B (es)
IE (1) IE60387B1 (es)
IL (1) IL69202A (es)
MA (1) MA19895A1 (es)
MY (1) MY102920A (es)
NO (1) NO833198L (es)
NZ (1) NZ204952A (es)
PT (1) PT77265B (es)
ZA (1) ZA836658B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936699A (ja) * 1982-08-20 1984-02-28 Chemo Sero Therapeut Res Inst シヤトルベクタ−
JPS5931799A (ja) * 1982-08-16 1984-02-20 Science & Tech Agency Ｂ型肝炎ウイルス遺伝子を組込んだ組換えプラスミド
WO1986007384A1 (fr) * 1985-06-03 1986-12-18 Takeda Chemical Industries, Ltd. Procede de preparation de l'antigene p31 de surface du virus de l'hepatite b
WO1986003411A1 (fr) * 1984-12-12 1986-06-19 Takeda Chemical Industries, Ltd. Procede de preparation d'une nouvelle proteine
WO1986001534A1 (fr) * 1984-09-04 1986-03-13 Takeda Chemical Industries, Ltd. Adn recombinant et son utilisation
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
DE3677851D1 (de) * 1985-08-05 1991-04-11 Merck & Co Inc Verfahren zur steigerung der produktion von rekombinantem protein in hefearten der gattung saccharomyces.
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
ZA88488B (en) * 1987-01-30 1988-10-26 Smith Kline Rit Hepatitis b virus surface antigens and hybrid antigens containing them
ATE93891T1 (de) * 1987-03-09 1993-09-15 Merck & Co Inc Reinigung von rekombiniertem hepatitis-boberfl|chen-antigen.
NZ229260A (en) * 1988-06-03 1994-02-25 Merck & Co Inc Hepatitis b virus, expression cassette for pre-s domain, host cells and
US4962656A (en) * 1989-06-30 1990-10-16 The United States Of America As Represented By The United States Department Of Energy Control and monitoring method and system for electromagnetic forming process
LT3988B (en) 1992-02-17 1996-06-25 Fermentas Biotech Inst Recombinant plasmides pfs19, pfps2-48 and pjlfds1 codingsynthesis of human hepatite b of surfice virus antigenes, methods fof producing thereof
TW340132B (en) * 1994-10-20 1998-09-11 Ibm Structure for use as an electrical interconnection means and process for preparing the same
JP4028850B2 (ja) * 2004-02-04 2007-12-26 株式会社名機製作所 ディスク基板の成形用金型

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU44186B (en) * 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
GR76274B (es) * 1981-08-04 1984-08-04 Univ California
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
GB2125047B (en) * 1982-08-09 1986-02-19 Ciba Geigy Ag Yeast hybrid vectors and their use for the production of polypeptides

Also Published As

Publication number Publication date
AU584580B2 (en) 1989-06-01
KR840006014A (ko) 1984-11-21
JP2522825B2 (ja) 1996-08-07
ES532732A0 (es) 1985-10-16
ZA836658B (en) 1984-06-27
GR78982B (es) 1984-10-02
FI833205L (fi) 1984-03-09
JPH08317796A (ja) 1996-12-03
NO833198L (no) 1984-03-09
EP0106828A3 (en) 1985-11-21
JPH02116A (ja) 1990-01-05
JPH02231084A (ja) 1990-09-13
CA1222707A (en) 1987-06-09
IE832099L (en) 1984-03-08
EP0106828A2 (fr) 1984-04-25
DE3382704T2 (de) 1994-02-10
DK406483D0 (da) 1983-09-07
CY1932A (en) 1983-09-06
PT77265A (en) 1983-09-01
PT77265B (en) 1986-02-04
MY102920A (en) 1993-03-31
AU9001491A (en) 1992-02-27
ES8602120A1 (es) 1985-11-01
JPS5971694A (ja) 1984-04-23
ES8600939A1 (es) 1985-10-16
IE60387B1 (en) 1994-07-13
ES525439A0 (es) 1985-07-01
ES532730A0 (es) 1985-10-16
DK406483A (da) 1984-03-09
NZ204952A (en) 1986-05-09
ES8506350A1 (es) 1985-07-01
JP2702899B2 (ja) 1998-01-26
IL69202A (en) 1991-08-16
DE3382704D1 (de) 1993-08-26
JPH02464A (ja) 1990-01-05
FI833205A7 (fi) 1984-03-09
AU1569288A (en) 1988-07-28
AU3131889A (en) 1989-07-20
HU196625B (en) 1988-12-28
ES532731A0 (es) 1985-11-01
ATE91718T1 (de) 1993-08-15
FI833205A0 (fi) 1983-09-07
EP0106828B1 (fr) 1993-07-21
MA19895A1 (fr) 1984-04-01
AU1675083A (en) 1984-03-15
HK1004570A1 (en) 1998-11-27

Similar Documents

Publication Publication Date Title
EA200100425A1 (ru) Новые способы терапевтической вакцинации
ES487106A0 (es) Un metodo para producir al menos un polipeptido que muestra antigenicidad de hbv
ES2059565T3 (es) Virus mva de la vacuna, recombinante.
ES474849A1 (es) Mejoras en un proceso para la produccion de un producto que comprende un polipeptido especifico
ES8602121A1 (es) Procedimiento para producir un vehiculo de expresion para la formacion de uroquinasa humana
ES2029171A6 (es) Un procedimiento para preparar un polipeptido virico de hepatitis no a y no b post-transfusional (pt-nanbh)
FI932678A7 (fi) Alfaviruksiin perustuvia DNA-ilmentämissysteemejä
ATE123065T1 (de) Proteine und deren herstellung.
ES2075901T3 (es) Sistemas de expresion de virus recombinantes de arn con cadena negativa y vacunas.
ES2119776T3 (es) Proteina d- una proteina que une igd de haemophilus influenzae.
ES2102815T3 (es) Procedimiento para la obtencion de ectodominios nativos, oligomeros, glicosilados de proteinas de membrana virales, su utilizacion, en especial como vacuna contra el vih.
ES8404186A1 (es) "un procedimiento para obtener al menos un polipeptido que presenta la antigenicidad de los antigenos e del virus de la hepatitis b".
ES8600939A1 (es) Un procedimiento para preparar una vacuna para el virus de la hepatitis b
ES8500327A1 (es) Procedimiento para producir polipeptido
ES8802162A1 (es) Un procedimiento para la preparacion de una levadura trans- formada con un plasmido recombinante insertado con el gen del virus de la hepatitis b.
Momose et al. Identification of host factors that regulate the influenza virus RNA polymerase activity
SE8105516L (sv) Syntetisk dna och forfarande for framstellning derav
NO20032097D0 (no) Gj¶ravledet vaksine mot IPNV
KR880000579A (ko) 베리셀라-죠스터 바이러스의 생산방법
ES8600400A1 (es) Un procedimiento para la produccion de histidina
GB1469901A (en) Process for obtaining virus proteins
ES2061524T3 (es) Un vector plasmidico para la expresion en bacillus y empleado para la clonacion del gen estructural que codifica la hormona de crecimiento humana y un metodo para la produccion de la hormona.
JPS6486874A (en) Cloned dna containing transcription promoting factor s-ii, its fragment, preparation thereof, plasmid containing said cloned dna or fragment and method for diagnosing viral disease and cancer using said cloned dna or fragment
ES546597A0 (es) Un procedimiento para preparar un microorganismo hospedante transformado del genero sacharomyces.
ES8506094A1 (es) Un procedimiento para producir l-isoleucina

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970401